New brain scan for neurodegenerative diseases
Part of Brain & nervous system clinical trials.
This trial studies a new imaging agent that helps doctors see brain changes related to Alzheimer's, Parkinson's, and similar conditions. The goal is to improve diagnosis and monitoring of these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of a neurodegenerative condition (like Alzheimer's or Parkinson's) from a neurologist.
- If you are taking MAO-B inhibitors (such as selegiline, rasagiline, safinamide), you must be willing to stop taking them at least 14 days before the study starts.
- You cannot have had brain surgery, a brain cyst, a brain tumor, or other conditions that could affect the scan results.
- You must be comfortable with MRI scans and PET scans, and not have severe claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at early signs of brain diseases like Alzheimer's or Parkinson's before symptoms appear. It uses brain scans and blood tests to find markers that might help predict who will develop these conditions.
This study uses a special PET/CT brain scan to look at a protein called tau in people with memory/thinking and movement disorders. The results may help researchers understand how these diseases affect the brain and improve future diagnosis or care.
This study uses a special PET scan to look at a protein in the brain that is linked to certain movement and memory disorders. It aims to improve diagnosis of these conditions.
This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.
This study tests a new PET imaging agent called [18F]F-AraG to see if it can help spot changes in the brain linked to Alzheimer's disease. The trial is for people who may have Alzheimer's and uses a special scan to look for signs of inflammation or other immune activity in the brain.
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
Hear when a new Neurodegenerative Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.